Last reviewed 2026-04-20 · How we verify

Carboplatin, pemetrexed, docetaxel, paclitaxel

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Nausea
• Diarrhoea
• Constipation
• Fatigue
• Pruritus
• Anaemia
• Pyrexia
• Decreased appetite
• Asthenia
• Cough
• Dyspnoea
• Rash

Key clinical trials

• Study of Novel Treatment Combinations in Patients With Lung Cancer (PHASE2)
• AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer (PHASE1, PHASE2)
• A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC (PHASE2)
• A Study of ASP3082 in Adults With Advanced Solid Tumors (PHASE1)
• A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)] (PHASE2)
• A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer (PHASE1)
• An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer (PHASE2)
• Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Carboplatin, pemetrexed, docetaxel, paclitaxel CI brief — competitive landscape report
• Carboplatin, pemetrexed, docetaxel, paclitaxel updates RSS · CI watch RSS
• Amgen portfolio CI